

MEDINEX LIMITED

Incorporated in the Republic of Singapore
Registration No. 200900689W

COMPLETION OF THE ACQUISITION OF SHARES IN HEALTHCARE ESSENTIALS PTE LTD (“HEPL”)

The Board of Directors (the “**Board**”) of Medinex Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) refers to the announcement dated 8 October 2020 (“**Previous Announcement**”) in respect of the memorandum of understanding (“**MOU**”) in relation to the proposed subscription of shares in HEPL.

Unless otherwise defined, capitalised items used in this announcement shall have the same meaning as that in the Previous Announcement.

The Board wishes to announce that the Company has, today, completed the acquisition of 20% of the total issued share capital of HEPL (the “**HEPL Shares**”) from HEPL’s sole shareholder, Mr. Lim Chye Lai, Gjan (“**Mr. Lim**”) (the “**Investment**”). Under the non-binding terms of the MOU, it was initially envisaged that the Company would subscribe to new shares in the share capital of HEPL. In the course of negotiations, it was agreed that the Company would acquire existing shares from Mr. Lim instead.

Mr. Lim has also concurrently sold another 20% stake in HEPL to the Company’s controlling shareholder, HC Surgical Specialists Limited (“**HCSS**”), a company listed on the Singapore Exchange Securities Trading Limited (“**SGX-ST**”). HCSS is primarily engaged in the provision of endoscopic procedures and general surgery services with a focus on colorectal procedures across a network of clinics in Singapore.

Following the completion of the Investment, the shareholders of HEPL as at the date of this announcement are Mr. Lim, the Company and HCSS, each holding 60%, 20% and 20% of the total issued share capital of HEPL respectively. The Company, Mr. Lim and HCSS have, today, also entered into a shareholders’ agreement to regulate their relationships as shareholders of HEPL and the conduct of the business and affairs of HEPL. As disclosed in the Previous Announcement, the Investment will constitute an Interested Person Transaction (“**IPT**”) under Chapter 9 of the SGX-ST Listing Manual Section B: Rules of Catalist (“**Catalist Rules**”).

The total consideration for the HEPL Shares was S\$182,000 (the “**Purchase Consideration**”), being 20% of an amount which is two times of the net tangible asset (“**NTA**”) value of HEPL as at 31 August 2020, arrived at based on arm’s length discussions between Mr. Lim and the Company taking into consideration commercial practices for such acquisitions in the industry. The net asset value and NTA of HEPL as at 31 August 2020 were S\$455,097.

The Purchase Consideration, which was satisfied in cash and funded through the Company’s internal resources, represents 2.57% of the Group’s latest audited NTA as at 31 March 2020 of S\$7,071,151. Accordingly, the Investment is a non-disclosable transaction under Chapter 9 of the Catalist Rules.

The Investment also constitutes a “non-discloseable transaction” under Chapter 10 of the Catalist Rules.

Saved as disclosed in this announcement, none of the directors or controlling shareholders of the Company and their respective associates has any interest, direct or indirect (other than through their respective shareholdings (if any) in the Company), in the Investment.

By Order of the Board

Jessie Low Mui Choo
Executive Director and Chief Executive Officer
23 December 2020

This announcement has been prepared by the Company and reviewed by the Company’s sponsor, Novus Corporate Finance Pte. Ltd. (the “**Sponsor**”), in compliance with Rule 226(2)(b) of the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) Listing Manual Section B: Rules of Catalist.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made, or reports contained in this announcement.

The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, at 9 Raffles Place, #17-05 Republic Plaza Tower 1, Singapore 048619, telephone (65) 6950 2188.